Sydnexis
CA - Del MarBiotechnology
Focus: Sydnexis is a private biotechnology company focused on developing eyedrops to arrest myopia progression, addressing a significant unmet need in vision care. The company is pre-revenue and operating as a clinical-stage biotech with a single Phase 3 program.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
0
About Sydnexis
AI assessmentNot HiringNo open roles listed right now. Follow Sydnexis to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SYD-101 0.01%
NearsightednessClinical Trials (1)
NCT03918915The Safety and Efficacy of SYD-101 in Children With Myopia
Phase 3Help build intelligence for Sydnexis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.